155 related articles for article (PubMed ID: 38405098)
1. Dose-dependent, non-pigmenting fixed drug eruption with eczematous lesions induced by bosutinib: case report.
Youh J; Yamaguchi Y; Kawamura T; Hoshina D
Pan Afr Med J; 2023; 46():95. PubMed ID: 38405098
[TBL] [Abstract][Full Text] [Related]
2. Pseudoephedrine may cause "pigmenting" fixed drug eruption.
Ozkaya E; Elinç-Aslan MS
Dermatitis; 2011 May; 22(3):E7-9. PubMed ID: 21569741
[TBL] [Abstract][Full Text] [Related]
3. Unilateral non-pigmenting fixed drug eruption associated with cotrimoxazole.
Rasi A; Khatami A
Dermatol Online J; 2006 Oct; 12(6):12. PubMed ID: 17083892
[TBL] [Abstract][Full Text] [Related]
4. Case report: Severe non-pigmenting fixed drug eruption showing general symptoms caused by chondroitin sulfate sodium.
Otsuka H; Fukumoto T; Oka M; Nishigori C
Front Med (Lausanne); 2022; 9():1041492. PubMed ID: 36388904
[TBL] [Abstract][Full Text] [Related]
5. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review.
Cortes JE; Apperley JF; DeAngelo DJ; Deininger MW; Kota VK; Rousselot P; Gambacorti-Passerini C
J Hematol Oncol; 2018 Dec; 11(1):143. PubMed ID: 30587215
[TBL] [Abstract][Full Text] [Related]
6. The safety of Bosutinib for the treatment of chronic myeloid leukemia.
Kong JH; Khoury HJ; Kim AS; Hill BG; Kota V
Expert Opin Drug Saf; 2017 Oct; 16(10):1203-1209. PubMed ID: 28774214
[TBL] [Abstract][Full Text] [Related]
7. MULTIFOCAL FIXED DRUG ERUPTION MIMICKING ACQUIRED DERMAL MELANOCYTOSIS.
Kordeva S; Cardoso JC; Tchernev G
Georgian Med News; 2023 Feb; (335):13-16. PubMed ID: 37042581
[TBL] [Abstract][Full Text] [Related]
8. Fixed drug eruptions. Incidence, recognition, and avoidance.
Lee AY
Am J Clin Dermatol; 2000; 1(5):277-85. PubMed ID: 11702319
[TBL] [Abstract][Full Text] [Related]
9. Bosutinib for the treatment of chronic myeloid leukemia.
Doan V; Wang A; Prescott H
Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
[TBL] [Abstract][Full Text] [Related]
10. Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Khoury HJ; Gambacorti-Passerini C; Brümmendorf TH
Ann Oncol; 2018 Mar; 29(3):578-587. PubMed ID: 29385394
[TBL] [Abstract][Full Text] [Related]
11. Vulval fixed drug eruption due to paracetamol.
Drummond C; Fischer G
Australas J Dermatol; 2009 May; 50(2):118-20. PubMed ID: 19397565
[TBL] [Abstract][Full Text] [Related]
12. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
Kantarjian HM; Cortes JE; Kim DW; Khoury HJ; Brümmendorf TH; Porkka K; Martinelli G; Durrant S; Leip E; Kelly V; Turnbull K; Besson N; Gambacorti-Passerini C
Blood; 2014 Feb; 123(9):1309-18. PubMed ID: 24345751
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia.
Hino M; Matsumura I; Fujisawa S; Ishizawa K; Ono T; Sakaida E; Sekiguchi N; Tanetsugu Y; Fukuhara K; Ohkura M; Koide Y; Takahashi N
Int J Hematol; 2020 Jul; 112(1):24-32. PubMed ID: 32279228
[TBL] [Abstract][Full Text] [Related]
14. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
Gambacorti-Passerini C; Brümmendorf TH; Kim DW; Turkina AG; Masszi T; Assouline S; Durrant S; Kantarjian HM; Khoury HJ; Zaritskey A; Shen ZX; Jin J; Vellenga E; Pasquini R; Mathews V; Cervantes F; Besson N; Turnbull K; Leip E; Kelly V; Cortes JE
Am J Hematol; 2014 Jul; 89(7):732-42. PubMed ID: 24711212
[TBL] [Abstract][Full Text] [Related]
15. A case of fixed drug eruption secondary to quinine in tonic water presenting to a sexual health clinic.
Lonsdale-Eccles E; Wallett A; Ward AM
Sex Transm Infect; 2014 Aug; 90(5):356-7. PubMed ID: 24583965
[TBL] [Abstract][Full Text] [Related]
16. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Dyagil I; Glushko N; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Reilly L; Jeynes-Ellis A; Leip E; Bardy-Bouxin N; Hochhaus A; Brümmendorf TH
J Clin Oncol; 2018 Jan; 36(3):231-237. PubMed ID: 29091516
[TBL] [Abstract][Full Text] [Related]
17. A first case of fixed drug eruption due to Tamsulosin.
Montazer F; Jahani Amiri K; Mofarrah R; Ahmadi A; Nouripour B; Mofarrah R
J Cosmet Dermatol; 2020 May; 19(5):1143-1145. PubMed ID: 31541583
[TBL] [Abstract][Full Text] [Related]
18. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
Cortes JE; Kim DW; Kantarjian HM; Brümmendorf TH; Dyagil I; Griskevicius L; Malhotra H; Powell C; Gogat K; Countouriotis AM; Gambacorti-Passerini C
J Clin Oncol; 2012 Oct; 30(28):3486-92. PubMed ID: 22949154
[TBL] [Abstract][Full Text] [Related]
19. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Hill BG; Kota VK; Khoury HJ
Expert Rev Anticancer Ther; 2014 Jul; 14(7):765-70. PubMed ID: 24875651
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.
Takahashi N; Cortes JE; Sakaida E; Ishizawa K; Ono T; Doki N; Matsumura I; García-Gutiérrez V; Rosti G; Ono C; Ohkura M; Tanetsugu Y; Viqueira A; Brümmendorf TH
Int J Hematol; 2022 Jun; 115(6):838-851. PubMed ID: 35235189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
